Can a Triple-Drug cocktail slow advanced stomach cancer?
NCT ID NCT00183898
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of three FDA-approved drugs—oxaliplatin, capecitabine (Xeloda), and cetuximab—can slow tumor growth in people with advanced or metastatic gastric or gastroesophageal cancer that has not been treated with chemotherapy before. The study measures how long it takes for the cancer to progress, how many tumors shrink, and how long patients live. Researchers are also looking at genetic markers in tumors and blood to see if they can predict who will benefit from the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of three drugs: oxaliplatin, capecitabine (Xeloda), and cetuximab
- What this could lead to
- If successful, this drug combination could offer a new first-line treatment option for people with advanced gastric or gastroesophageal cancer, potentially slowing tumor growth and extending survival.
- What could go wrong
- This is an early-phase (phase 2) trial with a small number of participants, so results may not apply to all patients. The drugs are not yet approved for this cancer type and may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
U.S.C./Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can a new drug combo shrink Hard-to-Treat tumors?